@article{ACS16535,
author = {Vedran Savic and Alberto Pozzoli and Gökhan Gülmez and Halil Demir and Nikola Batinkov and Shingo Kuwata and Alberto Weber and Rolf Vogel and Felix Tanner and Michel Zuber and Francesco Maisano and Maurizio Taramasso},
title = {Transcatheter mitral valve chord repair},
journal = {Annals of Cardiothoracic Surgery},
volume = {7},
number = {6},
year = {2018},
keywords = {},
abstract = {The field of mitral valve disease diagnosis and management is rapidly evolving. New understanding of pathophysiology and improvements in the adoption of sophisticated multimodality imaging modalities have led to early diagnosis and to more complex treatment. The most common cause of mitral regurgitation (MR) in the western world is in the primary alteration of the valve, which leads to degenerative leaflet prolapse due to chordal elongation or rupture and annular dilatation. Untreated, significant MR has a negative impact prognosis, leading to reduction of survival. In the setting of degenerative MR, surgical repair currently represents the standard of care. Treatment of asymptomatic patients with severe MR in the Valve Center of Excellence, in which successful repair reaches more than 95% and surgical mortality less than 1%, symbolizes the direction for the next years. Transcatheter mitral valve repair with different devices, more recently the chordal replacement ones, is providing good outcomes and became a therapeutic option in high-risk patients with degenerative MR. In the future, more advances are expected from further development of interventional techniques, careful evaluation and better patient selection. This review will focus on long-term surgical outcomes of mitral valve repair with artificial chordae and on the emerging transcatheter chordal repair devices as therapeutic options for degenerative MR patients.},
issn = {2304-1021}, url = {https://www.annalscts.com/article/view/16535}
}